H.C. Wainwright Remains a Hold on Syros Pharmaceuticals (SYRS)

By Carrie Williams

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Syros Pharmaceuticals (SYRSResearch Report), with a price target of $10. The company’s shares closed yesterday at $6.90.

Fein commented:

“Our price target of $10/share ($4.0 from tamibarotene + $3.4 from platform + $2.6 in cash) is based on a discounted cash flow analysis (2019-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.”

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.4% and a 46.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Syros Pharmaceuticals with a $11.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.86 and a one-year low of $5.17. Currently, Syros Pharmaceuticals has an average volume of 140.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.